

Original Article Asian Pacific Journal of Tropical Medicine

doi: 10.4103/apjtm.apjtm_871_23

Prognostic value of N-terminal pro B-type natriuretic peptide and troponin I in children with dengue shock syndrome

Truyen Phuoc $Le^{1,2\# \boxtimes}$, Phung Nguyen The Nguyen^{1,2#}

¹University of Medicine and Pharmacy at Ho Chi Minh city, Ho Chi Minh City, Vietnam ²Children's Hospital 1, Ho Chi Minh City, Vietnam

ABSTRACT

Objective: To investigate the contribution of *N*-terminal pro B-type natriuretic peptide (NT-pro BNP) and troponin I to mortality in children with dengue shock syndrome.

Methods: A longitudinal study was conducted on children with dengue shock syndrome in a hospital in southern Vietnam. Detailed clinical histories, physical examinations, and laboratory parameters, including NT-pro BNP and troponin I, were recorded. A comparison between survival and non-survival was carried out to identify factors influencing mortality.

Results: A total of 107 patients with a median age of 9 years were included in the study. Among them, 63.6% (68/107) presented with compensated shock, 36.4% (39/107) had hypotensive shock, 23.4% (25/107) required mechanical ventilation, and 12.1% (13/107) died. The NT-pro BNP levels were 3.9 pmol/L (IQR: 1.9, 10.3) and 15.2 pmol/L (5.8, 46.3), while the median high sensitivity troponin I levels were 20 pg/L (6, 95) and 62 pg/L (12, 325) at the first and second measurements, respectively. The mortality group exhibited higher rates of hypotensive shock, prolonged shock, lactate levels, liver damage, NT-pro BNP, and troponin I levels. Hypotensive shock (*OR* 12.96, 95% *CI* 2.70-62.30, *P*=0.004), prolonged shock (*OR* 39.40, 95% *CI* 6.68-232.70, *P*<0.001), AST > 1000 IU/L (*OR* 9.50, 95% *CI* 2.63-34.34, *P*=0.041), and NT-pro BNP > 7 pmol/L (*OR* 44.40, 95% *CI* 5.44-362.20, *P*=0.001) were identified as predictive factors for mortality in dengue shock syndrome.

Conclusions: The NT-pro BNP level could serve as a potential biomarker for predicting mortality in children with dengue shock syndrome.

KEYWORDS: Dengue shock syndrome; Cardiac enzyme; NT-pro BNP; Troponin I

1. Introduction

Dengue is a significant global tropical disease, primarily prevalent in the Asia-Pacific region. It imposes a substantial burden on healthcare systems, households, and economies[1,2]. Annually, over 50 million cases are reported in dengue-endemic areas, with Vietnam experiencing a fivefold increase in 2022 compared to 2021[3]. Dengue manifests in various clinical forms, from mild to severe, highlighting the critical need for early detection, particularly in resource-limited settings. Current methods, including the World Health Organization (WHO)'s warning signs, lack sensitivity in the early stages. There is an urgent demand for a reliable biomarker to improve the early management of severe dengue cases.

Significance

This study investigates the prognostic value of NT-proBNP and troponin I in predicting mortality among children with dengue shock syndrome (DSS). Our findings reveal that elevated levels of NT-proBNP are significantly associated with increased mortality risk in pediatric DSS cases. The significance of this research lies in its potential to enhance early risk stratification and guide more targeted therapeutic interventions in managing DSS, ultimately aiming to reduce the mortality rate in affected children. This underscores the critical role of NT-proBNP as a biomarker in the clinical management of DSS.

For reprints contact: reprints@medknow.com

O2024 Asian Pacific Journal of Tropical Medicine Produced by Wolters Kluwer-Medknow.

apjtm.org

^{*}These authors contributed equally to the work.

To whom correspondence may be addressed. E-mail: dr.letruyen@ump.edu.vn; dr.letruyen@gmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

How to cite this article: Truyen PL, Nguyen PNT. Prognostic value of *N*-terminal pro B-type natriuretic peptide and troponin I in children with dengue shock syndrome. Asian Pac J Trop Med 2024; 17(4): 166-172.

Article history: Received 19 November 2023 Revision 2 April 2024 Accepted 22 April 2024 Available online 29 April 2024

In recent years, there has been increased recognition of myocarditis as a potentially life-threatening complication of dengue infection. Researchers and healthcare professionals are increasingly investigating the link between dengue and myocarditis, with an estimated prevalence of around 12%, particularly higher among children, despite varying diagnostic criteria in studies. Additionally, myocarditis in dengue patients was linked to an increased risk of severity (relative risk of 2.44) and mortality (relative risk of 19.41) when compared to dengue patients who did not exhibit signs of myocarditis^[4]. Troponin I is a specific cardiac troponin released from damaged cardiomyocytes. Therefore, troponin I is a suitable marker for detecting myocarditis or cardiac injury^[5,6].

In the treatment of dengue shock syndrome, intravenous fluid resuscitation is crucial^[2]. However, sometimes it is difficult to distinguish between pulmonary edema, acute respiratory distress syndrome, acute heart failure, or fluid overload in a patient with respiratory distress. *N*-terminal pro B-type natriuretic peptide (NT-pro BNP) is an ideal biomarker for acute heart failure, as it is released in response to myocardial stretch when there is fluid overload in the circulation^[7,8].

Until now, there have been some studies on NT-pro BNP and troponin I in dengue patients, but almost no studies have specifically focused on NT-pro BNP and troponin I in dengue shock syndrome. The objective of this study was to assess NT-pro BNP and troponin I levels in children with dengue shock syndrome to evaluate their importance in classifying patients with dengue shock. Additionally, the study aimed to explore the potential of NT-pro BNP and troponin I as dependable biomarkers for early-phase prediction of mortality in dengue shock syndrome.

2. Subjects and methods

2.1. Study design

A longitudinal study was conducted in the Emergency Department and Intensive Care Unit at Children's Hospital 1 at Ho Chi Minh city, Vietnam for 2 years from January 2021 to December 2022.

2.2. Ethics statement and informed consent

The study was approved by the Ethics Committee of University of Medicine and Pharmacy at Ho Chi Minh city with protocol ID 2130-DHYD and was registered in ClinicalTrials.gov with ID NCT04837430. Patient recruitment was carried out with prior authorization from the Ethics Committee of Children's Hospital 1, identified by ID CS/N1/21/04. Informed consent, which included a thorough explanation, was obtained from all patients and their parents. The details of the reports were kept completely confidential.

2.3. Participants characteristics

This prospective study included all children aged from 1 month to 16 years old who were diagnosed with dengue shock syndrome and admitted to the Emergency Department of Children's Hospital 1. Dengue-positive cases were confirmed through clinical examination and the presence of either a positive NS1 antigen (Humasis Co., Ltd., South Korea) or positive dengue IgM antibodies (NovaLisa[™], Novatec German).

All patients enrolled in the study underwent a comprehensive clinical history assessment and full physical examination. Monitoring of patients occurred every 6 hours while they were in the Emergency Department (ED) and Intensive Care Unit (ICU) to observe hemodynamic changes and clinical signs. Prolonged shock was defined as shock that continues to occur in the ICU or persists for 6 hours after admission to the ED. Laboratory investigations included arterial blood gas, lactate, and serum albumin, which were performed every 6 hours. Additionally, complete blood counts (CBC), prothrombin time with international normalized ratio (PT with INR), activated partial thromboplastin time (aPTT), fibrinogen, and liver function tests, including serum alanine transaminase (ALT) and serum aspartate transaminase (AST), were conducted daily or as needed based on clinical requirements. Renal function tests, encompassing blood urea and serum creatinine, were also performed daily or as clinically indicated. All these tests were done at the Biochemistry Department at Children's Hospital 1.

NT-pro BNP and high sensitivity troponin I (troponin Ihs) measurements were taken at 6-hour and 18-hour for each subject. Approximately 2.5 mL of blood was collected in serum separator tubes (SST). After centrifugation, the serum specimens were stored at temperatures between -18 $^{\circ}$ C and -25 $^{\circ}$ C. The measurements of NT-pro BNP and troponin Ihs were conducted using the ARCHITECT system 2R10 by Abbott. NT-pro BNP and troponin Ihs tests were performed at the Biochemistry Department at Cho Ray hospital. An NT-pro BNP level exceeding 7 pmol/L was considered abnormal, while a troponin Ihs level surpassing 100 pg/L was also defined as abnormal.

2.4. Statistical analysis

Data analysis was performed using IBM SPSS Statistics software version 26.0 for Mac (SPSS Inc., Chicago, IL, USA). Categorical

variables were presented as frequencies and percentages. Continuous variables with non-normal distributions were expressed as median (interquartile range, IQR), while continuously normally distributed variables were expressed as mean \pm standard deviation. For comparisons, the frequencies of categorical variables were analyzed using Pearson χ^2 or Fisher's exact test when appropriate. The means of two continuous, normally distributed variables were compared using independent samples Student's *t*-test, while the Mann-Whitney *U* test was employed to compare means of two groups of variables that were not normally distributed. A value of *P*<0.05 was considered significant.

3. Results

3.1. Patient demographic and baseline characteristics

A total of 107 patients were enrolled in this study. The median age was 9.0 years (IQR: 6.4, 11.7), with the majority of patients being older than 5 years old (79.0%). Among the 107 patients, 65 (60.7%) were males, and 42 (39.3%) were females. The median duration of illness at the time of admission was 5 days (IQR: 4, 5), with the majority of cases occurring on the 4th and 5th days (79.0%). The most common chief complaint was lethargy, presented in 51 patients (47.7%). The second most common symptom was abdominal pain in 20 patients (18.7%), followed by persistent vomiting in 17 patients (15.9%), fever in 12 patients (11.2%), cold extremities in 4 patients (3.7%), seizures in 2 patients (1.9%), and diarrhea in 1 patient (0.9%). Overall, 68 patients (63.6%) presented with compensated shock, while 39 patients (36.4%) had hypotensive shock. Regarding nutritional status, 6.5% of patients were undernourished (7 patients), 24.3% were of normal weight (26 patients), 11.2% were overweight (12 patients), and 57.9% were obese (62 patients).

At the time of admission, 72.9% of patients had age-adjusted hypotension (n=78), 54.2% of patients had tachycardia (n=58). Notably, 64.4% (n=69) of the patients were in shock at the time of admission. Additionally, 17.8% experienced a change in mental state (n=19). Concerning peripheral pulse volume, 62.6% had weak or absent pulses (n=67). About 77.6% of patients had cool peripheries or cold extremities (n=83). In terms of respiratory rate, 55.1% had tachypnea (n=59), although all patients had good oxygen saturation.

After 6 hours, 25.2% of patients still had age-adjusted hypotension, and 21.5% of patients continued to have tachycardia. Furthermore, 15.9% experienced a change in mental state (n=17), 4.7% had weak or absent peripheral pulses (n=5), and 12.1% still had cool peripheries or cold extremities (n=13). Shock was observed in 7.5% (n=8) of the patients after 6 hours post-admission (prolong shock). Regarding respiratory rate, 66.4% had tachypnea (n=71), but all patients maintained good oxygen saturation, with a mean SpO₂ of 99% (IQR: 98%, 100%).

Regarding laboratory parameters, the median lactate level was 3.31 (2.07, 5.33) mmol/L, with 39.3% (*n*=42) of patients having lactate

levels exceeding 4 mmol/L. Hepatic involvement was reflected in AST levels, which had a median of 313 (131, 1053) IU/L, and ALT levels, with a median of 149 (53, 384) IU/L. Notably, 25.3% (n=27) of patients had AST levels exceeding 1 000 IU/L, while 11.2% (n=12) had ALT levels surpassing 1 000 IU/L. The median albumin level was 2.38 g/L (1.71, 3.05), and 36.4% (n=39) of patients had albumin levels below 2 g/L. The median CRP level was 4.0 (2.3, 8.5) mg/L. In arterial blood gas analysis, the median pH was 7.47 (7.42, 7.50) with 9.3% (n=10) of patients exhibited a pH lower than 7.3, and the median base excess was -5.5 (-10.0, 12.5). Over half of the patients (53.3%, n=57) had BE levels below -5. Furthermore, the INR was 1.39 (1.12, 1.80) with 36.4% (n=39) over 1.50. Meanwhile, hematocrit was 0.48 (0.41, 0.53), with 30.8% (n=33) having hematocrit higher than 50%, and platelets were 23 (16, 38) K/mcL, with 89.7% (n=96) having platelets lower than 50 K/mcL.

Regarding treatment, total fluid resuscitation was 193 (165, 253) mL/kg in 36.5 (32.0, 45.0) hours. The velocity of intravenous fluid resuscitation at 6-hour and 12-hour intervals was 5.00 (4.17, 6.25) mL/kg/h and 4.00 (3.00, 5.09) mL/kg/h, respectively. The rate of inotropes/vasopressor usage was 25.2%, and the rate of mechanical ventilation was 23.4% (Table 1).

Table 1. Baseline characteristics of the study patients.

Characteristics	Median (IQR)
Age, years	9.0 (6.4, 11.7)
Days from onset	5 (4, 5)
BMI, kg/m ²	21.7 (18.0, 24.9)
Overweight-obesity [*]	74 (69.2)
Hypotensive shock [*]	39 (36.4)
Shock at admit [*]	69 (64.4)
Prolong shock [*]	8 (7.5)
Lactate, mmol/L	3.31 (2.07, 5.33)
pH	7.47 (7.42, 7.50)
Base excess	-5.5 (-10.0, 12.5)
Albumin, g/L	2.38 (1.71, 3.05)
AST, IU/L	313 (131, 1053)
$AST > 120 IU/L^*$	83 (77.6)
ALT, IU/L	149 (53, 384)
CRP, mg/L	4.0 (2.3, 8.5)
International normalized ratio	1.39 (1.12, 1.80)
WBC, K/mcL	5.8 (4.1, 8.1)
Hematocrit	0.48 (0.41, 0.53)
Platelets, K/mcL	23 (16, 38)
Total fluid resuscitation, mL/kg	193 (165, 253)
Duration fluid resuscitation, hours	36.5 (32.0, 45.0)
Total fluid h12, mL/kg	144 (111, 205)
Velocity of fluid resuscitation at h6, mL/kg/hours	5.00 (4.17, 6.25)
Velocity of fluid resuscitation at h12, mL/kg/hours	4.00 (3.00, 5.09)
Inotropes-vasopressor*	27 (25.2)
Mechanical ventilation [*]	25 (23.4)
Troponin Ihs 1, pg/L	20 (6, 95)
Troponin Ihs 2, pg/L	62 (12, 325)
NT-proBNP 1, pmol/L	3.9 (1.9, 10.3)
NT-proBNP 2, pmol/L	15.2 (5.8, 46.3)

^{*}Data were expressed as *n* (%), *n*=107. BMI: body mass index; AST: aspartate aminotransferase; ALT: alanine transaminase; CRP: C-reactive protein; WBC: white blood cell count; troponin Ihs 1 and troponin Ihs 2: the concentrations of troponin Ihs measured at 6 hours and 18 hours, respectively; NT-proBNP 1 and NT-proBNP 2: the concentrations of NT-proBNP measured at 6 hours and 18 hours, respectively.

3.2. NT-pro BNP and troponin Ihs levels

The median NT-pro BNP level was 3.9 pmol/L (1.9, 10.3) at the initial measurement and 15.2 pmol/L (5.8, 46.3) at the subsequent measurement. Meanwhile, the median troponin Ihs level was 20 pg/L (6, 95) at the initial measurement and 62 pg/L (12, 325) at the subsequent measurement (Table 1). 29.9% (n=32) and 72.0% (n=77) of the subjects had abnormal NT-pro BNP levels during the initial and subsequent measurements, respectively. Additionally, 22.4% (n=24) and 42.1% (n=45) of the subjects had abnormal troponin Ihs levels during the initial and subsequent measurements, respectively.

3.3. Predictors of mortality of dengue

The overall mortality rate in our study was 12.1% (13/107), with 7 males and 6 females. All of these patients were in the ventilated group, and they received intravenous fluid resuscitation of 504 mL/kg (IQR: 368, 674) over 50 hours (IQR: 45, 69), with a velocity of intravenous fluid resuscitation at 9 mL/kg per hour. Additionally, all of these patients received vasopressor and inotropic therapies,

Table 2. Comparison between survival and non-survival groups

including adrenaline in 11 cases, noradrenaline in 10 cases, dobutamine in 9 cases, and dopamine in 8 cases.

As discribed in Table 2, when we compared the mortality group to the survival group, the rates of hypotensive shock, prolonged shock, lactate level, AST level, NT-pro BNP, and the amount of intravenous fluid resuscitation were higher in the mortality group. The patients in the non-survival group tend to experience shock in the early days of illness, typically on day 4 or day 3. As a result, the duration of plasma leakage is longer for this group. In contrast, the survival group tends to develop shock later in the course of the disease (P<0.05). While the percentage of shock at admission did not differ between the two groups (P=0.813), the percentages of both hypotensive shock and prolonged shock were higher in the non-survival group (P<0.001). Most patients in the survival group presented with compensated shock at admission.

Regarding laboratory findings, the non-survival group showed more severe indicators of shock, with higher lactate levels (10.40 mmol/L *vs.* 3.13 mmol/L), lower pH values (7.32 *vs.* 7.48), and reduced base excess levels (-15.9 *vs.* -4.9) compared to the survival group. Furthermore, the non-survival group displayed more pronounced

Characteristics	Survival (n=94)	Non-survival (n=13)	Р
Clinical outcomes			
Age, years	9.1 (6.8, 12.2)	4.6 (3.6, 9.8)	0.024
Days from onset	5 (4, 5)	4 (3, 5)	0.025
BMI, kg/m ²	22.2 (18.2, 25.2)	20.8 (16.7, 23.7)	0.326
Hypotensive shock [*]	28 (29.8)	11 (84.6)	< 0.001
Shock at admit [*]	61 (64.9)	8 (61.5)	0.813
Prolonged shock [*]	2 (2.1)	6 (46.2)	< 0.001
Abnormal SIPA T0 [*]	84 (89.4)	12 (92.3)	0.743
Abnormal SIPA T6 [*]	26 (27.7)	10 (76.9)	< 0.001
Laboratory investigations			
Lactate, mmol/L	3.13 (2.01, 4.97)	10.40 (4.70, 13.10)	< 0.001
pH	7.48 (7.44, 7.51)	7.32 (7.18, 7.39)	< 0.001
Base excess	-4.9 (-8.8, -1.6)	-15.9 (-22.0, -9.0)	< 0.001
Albumin, g/L	2.47 (1.76, 3.20)	1.66 (1.10, 2.60)	0.011
AST, IU/L	250 (115, 778)	1393 (542, 4240)	< 0.001
AST >1 000 IU/L [*]	18 (19.1)	9 (69.2)	< 0.001
ALT, IU/L	143 (48, 343)	551 (234, 1396)	< 0.001
Troponin Ihs 1, pg/L	18.5 (5.2, 86.0)	95.0 (26.0, 342.0)	0.016
Troponin Ihs 2, pg/L	39.9 (11.4, 264.0)	342.0 (117.0, 667.0)	0.006
NT-proBNP 1, pmol/L	3.5 (1.9, 6.4)	127.0 (13.7, 439.0)	< 0.001
NT-proBNP $1 > 7 \text{ pmol/L}^*$	20 (21.3)	12 (92.3)	< 0.001
NT-proBNP 2, pmol/L	13.6 (5.5, 29.6)	689.0 (35.0, 1061.0)	< 0.001
Freatment			
Total fluid resuscitation, mL/kg	183 (161, 218)	504 (368, 674)	< 0.001
Duration fluid resuscitation, hours	36 (31, 43)	50 (45, 69)	0.001
Total fluid h12, mL/kg	136 (110, 182)	223 (207, 308)	< 0.001
Velocity of fluid resuscitation at h6, mL/kg/hour	5.00 (4.00, 5.83)	8.33 (6.29, 16.67)	< 0.001
Velocity of fluid resuscitation at h12, mL/kg/hour	3.71 (3.00, 5.00)	10.00 (5.00, 16.25)	< 0.001
Mechanical ventilation [*]	12 (12.8)	13 (100.0)	< 0.001
Vasopressor/inotropes*	14 (14.9)	13 (100.0)	< 0.001

^{*}Data were expressed as n (%); otherwise they were expressed as median (IQR). BMI: body mass index; AST: aspartate aminotransferase; ALT: alanine transaminase; Abnormal SIPA T0 and Abnormal SIPA T6: abnormal pediatric age-adjusted shock index at 0 hour and 6 hours; troponin Ihs 1 and troponin Ihs 2: the concentrations of troponin Ihs measured at 6 hours and 18 hours, respectively; NT-proBNP 1 and NT-proBNP 2: the concentrations of NT-proBNP measured at 6 hours, respectively.

Tabl	e 3.	Factors	influencing	mortality	in dengue	shock synd	rome.
------	------	---------	-------------	-----------	-----------	------------	-------

Characteristics	Survival (n=94)	Non-survival (n=13)	OR	95% CI	В	Р
Hypotensive shock	29.8%	84.6%	12.96	2.70-62.30	0.222	0.004
Prolonged shock	2.1%	46.2%	39.40	6.68-232.70	0.343	< 0.001
AST > 1000 IU/L	19.1%	69.2%	9.50	2.63-34.34	0.162	0.041
NT-pro BNP > 7 pmol/L	21.3%	92.3%	44.40	5.44-362.20	0.281	0.001

liver damage, indicated by elevated AST and ALT levels, along with increased plasma leakage characterized by lower serum albumin levels. Simultaneously, NT-pro BNP and troponin I were higher in the non-survival group compared to the survival group (Table 2).

Regarding treatment, the non-survival group received a greater overall volume of fluid for resuscitation and had a longer duration of fluid resuscitation compared to the survival group. Intubation and ventilation were necessary for 100% of the non-survival group, while only 12.8% of the survival group required this intervention, typically initiated around 18 hours after admission to the Emergency Department. As a result, we conducted an analysis using the amount of fluid administered before this time as a predictive factor for intubation. Our findings indicated that the total fluid volume administered within the initial 12 hours and the rate of fluid administration at 6 and 12 hours were higher in the nonsurvival group. Essentially, an inability to reduce the rate of fluid resuscitation at 6 and 12 hours suggested that these patients might require intubation and ventilation.

In the end, as discribed in Table 3, regression analysis was conducted to identify the factors influencing mortality in dengue shock syndrome. Initially, all variables underwent univariate regression analysis, and only those variables that showed significance were subsequently subjected to multivariate analysis. At the time of the analysis, it was determined that hypotensive shock, prolonged shock, AST levels above 1 000 IU/L, and abnormal NT-pro BNP (exceeding 7 pmol/L) were predictive factors for mortality in dengue shock syndrome.

4. Discussion

This study was a longitudinal investigation conducted over a duration of two years, spanning from January 2021 to December 2022, and it encompassed a sample of 107 children diagnosed with dengue shock syndrome. The median age was 9 years, dominant in children older than 5 years and prominent in male. This result was familiar with Saiful Islam in Bangladesh, Nutnicha Preeprem in Thailand and Nguyen Phung in Vietnam[9–11]. This distribution highlights that dengue shock syndrome can affect a broad age range in children, with the majority falling within this relatively older age group. Typically, children in this study presented with dengue shock syndrome on the fourth or fifth day of the disease. Chief complaints

and symptoms shed light on the clinical presentation of these children. Lethargy was the most common chief complaint, reported in 47.7% of patients, followed by abdominal pain, which was the second most frequent symptom, occurring in 18.7% of cases. These signs and symptoms align with the warning signs outlined in the WHO classification for dengue management[2]. The prevalence of nutritional status among the study participants is a notable observation. Among them, 11.2% were overweight, and 57.9% were obese. These characteristics are known predisposing factors for severe dengue[12].

Our study was conducted in dengue shock patients, so the signs and symptoms of peripheral vascular collapse were evident. The median systolic blood pressure was notably low, with 72.9% of patients had hypotension. Tachycardia was prevalent in 54.2% of cases, indicating increased stress on the cardiovascular system. A significant proportion of patients exhibited altered mental states, weak or absent peripheral pulses, and cool extremities, all indicative of circulatory collapse. Neeraja and Menwal had the same findings when researching severe dengue patients[13,14]. While 55.1% had tachypnea, their maintained good oxygen saturation suggests that respiratory function remained relatively unaffected. Interestingly, within 6 hours, systolic blood pressure showed a moderate improvement, even though 25.2% still below the normal range. The pulse rate decreased, but tachycardia persisted in 21.5% of cases. The presence of such severe shock signs highlights the need for rapid and aggressive intervention in dengue shock syndrome cases to improve patient outcomes.

In our study, 39.3% had lactate levels higher than 4 mmol/L, and 53.3% had a base excess less than -5. Simultaneously, AST levels had a median of 313 (131, 1053) IU/L, with 25.3% of patients having AST levels exceeding 1000 IU/L. Researchers such as Mansanguan and Miranda also found a higher rate of liver damage in dengue shock syndrome patients[15,16]. The CRP level in our study was lower than that in Rao *et al*'s study, possibly due to the higher proportion of liver damage observed in our study[17]. Another explanation is that Rao *et al*. focused on adult patients with many chronic diseases, leading to a high baseline level of CRP, whereas our study specifically concentrated on children with a lower baseline CRP level.

The analysis of NT-pro BNP and troponin Ihs levels in children with dengue shock syndrome offers valuable insights into their prognostic significance. NT-pro BNP levels displayed a notable increase between the initial and subsequent measurements, indicating a progression in the severity of the disease. Similarly, troponin Ihs levels exhibited an increase, although not as pronounced. A considerable proportion of patients exhibited abnormal levels, particularly during the subsequent measurements, underscoring these biomarkers' role as indicators of cardiac involvement in dengue shock syndrome. Atmaja and Bhatt found troponin I, NT-pro BNP corresponds to an increase in the dengue severity level in patients with dengue shock syndrome[18,19].

Our study found that in children with dengue shock syndrome, early and prolonged shock experiences are associated with a higher risk of mortality. Laboratory findings revealed that non-survivors had more severe shock indicators and cardiac involvement. Additionally, these patients received more extensive fluid resuscitation and required mechanical ventilation. Regression analysis identified hypotensive shock, prolonged shock, elevated AST levels, and high NT-pro BNP as predictive factors for mortality. Early recognition of these factors can improve risk assessment and guide interventions to enhance patient outcomes. The patients in our study are more severe than those in Nguyen Phung's study, with 77.6% of our patients having hepatic damage, which was defined when patients had AST or ALT levels > 120 UI/L, compared to 60% in Nguyen Phung's study[20].

Regarding treatment, the non-survival group received greater volumes of fluid resuscitation over a longer duration. The need for intubation and mechanical ventilation was universal in the nonsurvival group, in contrast to the survival group, where only 12.8% of patients required this intervention, typically initiated around 18 hours after admission. Analysis using the amount of fluid administered within the initial 12 hours and the rates of fluid administration at 6 and 12 hours revealed significant differences between the two groups, underscoring the impact of fluid management on outcomes.

In the end, regression analysis highlighted specific factors predictive of mortality in dengue shock syndrome. These included hypotensive shock, prolonged shock, elevated AST levels above 1000 IU/L, and abnormal NT-pro BNP levels exceeding 7 pmol/L. Recognizing these factors can aid in early risk stratification and targeted interventions to improve patient outcomes.

Acknowledging the study's scope, a limitation is the modest tally of 25 cases requiring mechanical ventilation, suggesting the potential for deeper insights with a larger subset. Additionally, the assessment of NT-proBNP and troponin markers at only two intervals indicates a need for more frequent testing to enhance our understanding.

Conflict of interest statement

We declare no conflict of interests.

Funding

The authors received no extramural funding for the study.

Acknowledgments

We extend our gratitude to Dr. Nguyen Thi Mai Anh for participating as a content expert reviewer. We also acknowledge the cooperation and support of all healthcare workers at Children's Hospital 1 and Cho Ray Hospital for their dedicated efforts in the study.

Authors' contributions

All authors played significant roles in drafting, revising, and providing final approval for the article to be submitted. TPL contributed to the study's design, data acquisition, conducted data analysis, and interpreted the findings. NNTP contributed to the study's design and data interpretation.

References

- Guzman MG, Gubler DJ, Izquierdo A, Martinez E, Halstead SB. Dengue infection. *Nat Rev Dis Primers* 2016; 2(1): 16055.
- [2] World Health Organization. WHO guidelines approved by the Guidelines Review Committee. Dengue: guidelines for diagnosis, treatment, prevention and control. New edition. Geneva: World Health Organization; 2009.
- [3] World Health Organization. Dengue situation updates 2023 WHO regional office for the western Pacific. 2023. [Online]. Available from: https://apps. who.int/iris/handle/10665/365676. [Accessed on 10 November 2023].
- [4] Farrukh AM, Ganipineni VDP, Jindal U, Chaudhary A, Puar RK, Ghazarian K, et al. Unveiling the dual threat: Myocarditis in the spectrum of dengue fever. *Curr Probl Cardiol* 2023; **49**(1 Pt A): 102029.
- [5] Katrukha IA, Katrukha AG. Myocardial injury and the release of troponins I and T in the blood of patients. *Clin Chem* 2021; 67(1): 124-130.
- [6] Chaulin AM. Cardiac troponins metabolism: From biochemical mechanisms to clinical practice (literature review). *Int J Mol Sci* 2021; 22(20): 10928.
- [7] Pagel-Langenickel I. Evolving role of natriuretic peptides from diagnostic tool to therapeutic modality. *Adv Exp Med Biol* 2018; **1067**: 109-131.
- [8] Alcidi G, Goffredo G, Correale M, Brunetti ND, Iacoviello M. Brain natriuretic peptide biomarkers in current clinical and therapeutic scenarios of heart failure. *J Clin Med* 2022; 11(11): 3192.

[9] Islam S, Khan MAS, Badal MFA, Khan MZI, Gozal D, Hasan MJ.

Clinical and hematological profiles of children with dengue residing in a non-endemic zone of Bangladesh. *PLoS Negl Trop Dis* 2022; **16**(10): e0010847.

- [10]Preeprem N, Phumeetham S. Paediatric dengue shock syndrome and acute respiratory failure: A single-centre retrospective study. *BMJ Paediatr Open* 2022; 6(1): e001578.
- [11]Nguyen Phung NT, Kieu Pham TT, Tuan Tran D. Respiratory distress associated with dengue hemorrhagic fever on paediatric patients: Learning from a provincial hospital in southern Vietnam. *Arch Pharma Pract* 2019; **10**(3): 92-97.
- [12]Kurnia B, Suryawan IWB. The association between obesity and severity of dengue hemorrhagic fever in children at Wangaya General Hospital. *Open Access Maced J Med Sci* 2019; 7(15): 2444-2446.
- [13]Neeraja M, Iakshmi V, Teja VD, Lavanya V, Priyanka EN, Subhada K, et al. Unusual and rare manifestations of dengue during a dengue outbreak in a tertiary care hospital in South India. *Arch Virol* 2014; **159**(7): 1567-1573.
- [14]Menwal U, Rawat A, Rawat A, Chandar V. Cardiac manifestations of dengue fever in pediatrics age group. *Indian J Child Health* 2020; 7(9): 363-365.
- [15]Mansanguan C, Hanboonkunupakarn B, Muangnoicharoen S, Huntrup A, Poolcharoen A, Mansanguan S, et al. Cardiac evaluation in adults with dengue virus infection by serial echocardiography. *BMC Infect Dis* 2021; 21(1): 940.
- [16]Miranda CH, Borges Mde C, Matsuno AK, Vilar FC, Gali LG, Volpe GJ,

et al. Evaluation of cardiac involvement during dengue viral infection. *Clin Infect Dis* 2013; **57**(6): 812-819.

- [17]Rao R, Nayak S, Pandey AK, Kamath SU. Diagnostic performance of C-reactive protein level and its role as a potential biomarker of severe dengue in adults. *Asian Pac J Trop Med* 2020; **13**(8): 358-365.
- [18]Atmaja GT, Buntubatu S, Wijaya CS, Sudarmadi ANP, Laksono IS, Indrawanti R, et al. Comparison of cardiac marker profiles in dengue myocarditis. J Med Sci (Berkala Ilmu Kedokteran) 2023; 55(1). doi: 10.19106/JMedSci005501202304.
- [19]Bhatt M, Soneja M, Farooqui FA, Singla P, Vikram NK, Biswas A, et al. Myocarditis in admitted patients with dengue fever. *Infection* 2020; 48(6): 899-903.
- [20]Phung NTN, Vo DM, Le TN, Doan TT. Total serum cortisol level is low in children with severe dengue shock syndrome. *Trop Biomed* 2021; 38(3): 396-402.

Publisher's note

The Publisher of the *Journal* remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Edited by Zhang Q, Pan Y, Lei Y